ACCELERON PARTNERS WITH WESTWOOD & WILSHIRE TO FILL VICE PRESIDENT OF PHARMACOVIGILANCE

Acceleron, a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases, has hired Dr. Debashish Dey as the new Vice President of Pharmacovigilance. Dr. Dey has joined Acceleron from AveXis, Inc. where he served as the Vice President and Head of Global Patient Safety. Dr. Dey has a distinguished career starting in 2002 in Sweden first with AstraZeneca then Novartis as an epidemiologist before joining Eli Lilly in 2007 as a Medical Advisor. At Lilly, Dr. Dey took positions of increasing responsibility over 9-years, becoming Global Head of Patient Safety for multiple therapeutic areas by 2014. In addition, to Eli Lilly, Dr. Dey was the Global Head of Hematology Global Drug Safety at Shire. He is an MD PhD in Geriatric Medicine and has an MPH in Epidemiology.

The search was successfully led by Gerard Danishek for Westwood & Wilshire’s Life Sciences practice.

At Westwood & Wilshire, we recognize that people are an organization's top asset. We are passionate about delivering premier talent to the world’s most innovative companies. We are particularly focused on companies ranging from VC-backed start-ups to mid-sized commercial entities and our assignments range from C-Suite to mid-management. Our firm has offices in Los Angeles, Silicon Valley, and Seattle, serving clients on a local, national and global basis.